Long-term randomised comparison of clinical outcomes following ART initiation with triple-nucleoside (Combivir/Abacavir) or NNRTI-based (Combivir/Nevirapine) therapy in Africa: the NORA substudy of the DART trial

MOPEB057

AS Walker[1], P Munderi[2], C Kityo[3], AG Babiker[1], F Ssali[3], A Reid[4], H Grosskurth[2], P Mugyenyi[3], DM Gibb[1], CF Gilks[5] & the DART Trial Team

[1]MRC Clinical Trials Unit, London, UK; [2]MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda; [3]Joint Clinical Research Centre, Kampala, Uganda; [4]University of Zimbabwe, Harare, Zimbabwe; [5]Imperial College, London, UK

www.ctu.mrc.ac.uk/dart
Email:asw@ctu.mrc.ac.uk

Background: NORA trial design

- Nevirapine OR Abacavir (NORA) substudy
- 600 patients within the DART trial randomised to initiate ART with ZDV+3TC (combivir, CBV) plus
  - Abacavir (ABC)
  - Nevirapine (NVP)
- Primary and secondary endpoints: toxicity at 24 weeks (placebo-blinded)
- Continued open-label follow-up after 24 weeks for up to 5 years in DART

The question

- To 48 weeks, we observed
  - clear superiority of NVP over ABC in terms of VL <50 copies/ml (77% vs 62%) and CD4 increases (+173 vs +147 cells/mm^3)
  - trend towards superiority or superiority of ABC over NVP in terms of clinical outcomes, for example
    - Death: HR(ABC:NVP) = 0.55 (95% CI 0.24-1.25) p=0.15
    - Death/WHO 4: HR(ABC:NVP) = 0.60 (95% CI 0.34-1.05) p=0.07
    - Death/WHO 3/4: HR(ABC:NVP) = 0.67 (95% CI 0.46-0.96) p=0.03
- **QUESTION: How does clinical disease progression in ABC compare to that in NVP over the longer-term?**

The challenge: Structured Treatment Interruptions

- 813 (25%) DART patients with a good early response to ART (achieving CD4>300 cells/mm3 at 48 or 72 weeks) were randomised in a **conditional factorial (non-inferiority) design** between
  - continuous therapy (CT)
  - structured treatment interruptions (STIs)
    - 12 weeks on ART, 12 weeks off ART, etc
- **CT/STI randomisation stopped early in March 2006 showing inferiority of STIs on disease progression**
  - 2.6 fold increased rate of disease progression
  - CD4 count dropped by mean 150-200 cells/mm^3 during STI

PROBLEM 1

- CD4 response was better in NVP, so more patients achieved the CD4>300 cells/mm^3 threshold and were randomised in the CT/STI substudy in NVP than ABC

PROBLEM 2

- There was a **chance imbalance** in CT/STI randomisation between NVP and ABC, with even more NVP patients randomised to STI
  - CT/STI randomisation stratified by original allocation to LCM/CMO (factorial), centre and weeks of first-line ART (48/72) with variable block size (8,12); all other factors well balanced across CT/STI groups; no evidence of tampering with randomisation procedure integrated into trial database

Table 1: NORA patient characteristics

	ABC	NVP	Total
Total NORA patients	300 (100%)	300 (100%)	600 (100%)
Women	217 (72%)	213 (71%)	430 (72%)
Previously received sdNVP	4 (1%)	11 (4%)	15 (3%)
Median (IQR) pre-ART CD4	99(49-149)	99(40-145)	99(44-147)
Mean (SD) pre-ART $\log_{10}$ VL	5.4 (0.7)	5.4 (0.7)	5.4 (0.7)
Not randomised to CT/STI	211 (70%)	183 (61%)	394 (66%)
Randomised to CT/STI	89 (30%)	117 (39%)	206 (34%)
Randomised to CT	*53 (18%)*	*47 (16%)*	*100 (17%)*
Randomised to STI*	*36 (12%)*	*70 (23%)*	*106 (18%)*

* stopped all ART for 12 weeks out of every 24 weeks from 52 or 76 weeks after starting ART: mean 150-200 cell/mm^3 drop in CD4, 2.6 fold increased risk of disease progression

Twice as many NVP NORA participants underwent STIs compared with ABC



Statistical methods

- We adjusted Cox models for time-to-event outcomes for differential recruitment to STI/CT by **weighting**: specifically we excluded all follow-up after participants were randomised to STI, and probability up-weighted equivalent post-randomisation follow-up from participants randomised to CT. This effectively
  - treats the 53 ABC patients randomised to CT (Table 1) as if they were really the 89 ABC patients randomised to STI/CT in the statistical model
  - treats the 47 NVP patients randomised to CT (Table 1) as if they were really the 117 NVP patients randomised to STI/CT in the statistical model
  - randomisation ensures those randomised to CT are representative of the whole group randomised to STI/CT
- Simply including "randomised to STI", "randomised to CT", "not randomised" as a time-updated explanatory factor in the Cox model can produce biased estimates, because of **time-depending confounding**
  - estimates from models adjusted using time-updated explanatory factors were actually very similar to the unadjusted estimates

LIMITATION:

- **The unequal randomisation to STI between NVP and ABC happened: whilst statistical methods can be used to adjust for the imbalance, these rely on modelling assumptions**
  - the approach used here was validated in numerous simulations studies

Cotrimoxazole prophylaxis and mortality

- 2458 person-years (2103 excluding follow-up after randomisation to STI) accrued from ART initiation to 31/12/2008 (end of CMO/LCM follow-up)
  - median 4.5 years follow-up (IQR 4.3-4.7, maximum 5 years)

	Death	New/recurrent WHO4/death
Not adjusted for STIs		
Events	25 ABC, 31 NVP	54 ABC, 65 NVP
Rate/100 PY	2.0 vs 2.5	4.6 vs 5.8
HR(ABC:NVP) (95% CI)	0.80 (0.47-1.36) p=0.42	0.80 (0.56-1.15) p=0.24
% event-free at 4.5 years	91% vs 89%	81% vs 77%
HR(ABC:NVP) by time on ART	heterogeneity p=0.78	heterogeneity p=0.08
0-90 days	0.58 (0.23-1.48)	0.62 (0.32-1.18)
91 days - 1 year	0.49 (0.09-2.65)	0.82 (0.28-2.43)
1-2 years	1.22 (0.33-4.54)	0.45 (0.19-1.03)
2-3 years	0.59 (0.14-2.48)	0.62 (0.22-1.75)
3-4 years	1.66 (0.40-6.95)	3.59 (1.19-10.8)
4-5 years	1.05 (0.22-5.15)	1.04 (0.26-4.14)
Adjusted for STIs by weighting*		
Events*	26 ABC, 25 NVP	53 ABC, 54 NVP
Rate/100 PY*	2.1 vs 2.0	4.6 vs 4.8
HR(ABC:NVP) (95% CI)	1.04 (0.59-1.84) p=0.89	0.95 (0.64-1.42) p=0.82
% event-free at 4.5 years	91% vs 91%	81% vs 81%
HR(ABC:NVP) by time on ART	heterogeneity p=0.47	heterogeneity p=0.10
0-90 days	0.58 (0.23-1.48)	0.62 (0.32-1.18)
91 days - 1 year	0.49 (0.09-2.65)	0.82 (0.28-2.43)
1-2 years	1.63 (0.39-6.82)	0.67 (0.25-1.77)
2-3 years	1.45 (0.29-7.32)	0.83 (0.26-2.64)
3-4 years	2.89 (0.55-15.1)	5.20 (1.49-18.1)
4-5 years	2.18 (0.20-23.3)	1.11 (0.16-7.84)

* excluding all follow-up after participants were randomised to STI, and probability up-weighting equivalent post-randomisation follow-up from participants randomised to CT

Death

- Solid lines in (a) are the Kaplan-Meier **survival** estimate
- Dotted lines in (a) show the fit from a model[1] estimating the instanteous risk of death over time (the **hazard**; in (b))
- Estimated survival percentages from the model are shown in (a)
- Points in (a) & (b) show the actual death times
- The risk of death is higher in NVP shortly after starting ART **(A)**
- After 2 years the hazards cross, and the risk of death is higher in ABC: but rates are far lower than after starting ART **(B)**

[1] *Royston & Parmar Stat Med 2003*



New/recurrent WHO 4 or death

- Solid lines in (a) are the Kaplan-Meier **WHO-4-free survival** estimate
- Dotted lines in (a) show the fit from a model[1] estimating the instanteous risk of WHO-4/death over time (the **hazard**; in (b))
- Estimated percentages alive & WHO 4-free from the model are shown in (a)
- Points in (a) & (b) show the actual even times
- The risk is higher in NVP shortly after starting ART **(A)**
- After 2 years the hazards cross, and the risk is higher in ABC: but rates are far lower than after starting ART **(B)**



Conclusions

- **There was no statistically significant difference in the rate of new WHO 4 events/death or death between participants initiating ART with Combivir plus nevirapine versus abacavir through 5 years follow-up**
  - as a consequence of the large early differences and low long-term event rates, at 4.5 years 91% participants were estimated to be alive in both groups
  - those taking only NRTIs 1st-line have two new classes (bPI+NNRTI) for 2nd-line
  - nevirapine had clear superiority in terms of CD4 (and VL supression to 96 weeks): the unexpected failure of laboratory markers to predict clinical outcomes is unexplained and requires further evaluation
- **Including time-dependent factors in multivariable models is the standard method for adjustment in observational analyses, but provides incomplete adjustment for time-dependent confounders**
  - these may occur more frequently than is recognised, as here, so using weighting to adjust for post-baseline changes should be considered more

We thank all the patients and staff from all the centres participating in the DART trial. MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda: H Grosskurth, P Munderi, G Kabuye, D Nsibambi, R Kasirye, E Zalwango, M Nakazibwe, B Kikaire, G Nassuna, R Massa, K Fadhiru, M Namyalo, A Zalwango, L Generous, P Khauka, N Rutikarayo, W Nakahima, A Mugisha, J Todd, J Levin, S Muyingo, A Ruberantwari, P Kaleebu, D Yirrell, N Ndembi, F Lyagoba, P Hughes, M Aber, A Medina Lara, S Foster, J Amurwon, B Nyanzi Wakholi. Joint Clinical Research Centre, Kampala, Uganda: P Mugyenyi, C Kityo, F Ssali, D Tumukunde, T Otim, J Kabanda, H Musana, J Akao, , H Kyomugisha, A Byamukama, J Sabiiti, J Komugyena, P Wavamunno, S Mukiibi, A Drasiku, R Byaruhanga, O Labeja, P Katundu, S Tugume, P Awio, A Namazzi, GT Bakeinyaga, H Katabira, D Abaine,J Tukamushaba, W Anywar, W Ojiambo, E Angweng, S Murungi, W Haguma, S Atwiine,J Kigozi. University of Zimbabwe, Harare, Zimbabwe: A Latif, J Hakim, V Robertson, A Reid, E Chidziva, R Bulaya-Tembo, G Musoro, F Taziwa, C Chimbetete, L Chakonza, A Mawora, C Muvirimi, G Tinago, P Svovanapasis, M Simango, O Chirema, J Machingura, S Mutsai, M Phiri, T Bafana, M Chirara, L Muchabaiwa, M Muzambi. Infectious Diseases Institute (formerly the Academic Alliance) Makerere University, Mulago, Uganda: E Katabira, A Ronald, A Kambungu, F Lutwama, A Nanfuka, J Walusimbi, E Nabankema, R Nalumenya, T Namuli, R Kulume, I Namata, L Nyachwo, A Florence, A Kusiima, E Lubwama, R Nairuba, F Oketta, E Buluma, R Waita, H Ojiambo, F Sadik, J Wanyama, P Nabongo. The AIDS Support Organisation (TASO), Uganda: R Ochai, D Muhweezi. Imperial College , London, UK: C Gilks, K Boocock, C Puddephatt, C Grundy, J Bohannon. MRC Clinical Trials Unit, London, UK: J Darbyshire, DM Gibb, A Burke, D Bray, A Babiker, AS Walker, H Wilkes, M Rauchenberger, S Sheehan, C Spencer-Drake, K Taylor, M Spyer, A Ferrier, B Naidoo, D Dunn, R Goodall. DART Virology Group: P Kaleebu (Co-Chair), D Pillay (Co-Chair), V Robertson, D Yirrell, S Tugume, M Chirara, P Katundu, N Ndembi, F Lyagoba, D Dunn, R Goodall, A McCormick. DART Health Economics Group: A Medina Lara (Chair), S Foster, J Amurwon, B Nyanzi Wakholi, J Kigozi, L Muchabaiwa, M Muzambi. Independent DART Trial Monitors: R Nanfuka, C Mufuka-Kapuya. Trial Steering Committee: I Weller (Chair), A Babiker (Trial Statistician), S Bahendeka, M Bassett, A Chogo Wapakhabulo, J Darbyshire, B Gazzard, C Gilks, H Grosskurth, J Hakim, A Latif, C Mapuchere, O Mugurungi, P Mugyenyi; Observers: C Burke, M Distel, C Newland, S Rahim, J Rooney, M Smith, W Snowden, J-M Steens. Data and Safety Monitoring Committee: A Breckenridge (Chair), A McLaren (Chair-deceased), C Hill, J Matenga, A Pozniak, D Serwadda. Endpoint Review Committee: T Peto (Chair), A Palfreeman, M Borok, E Katabira. Funding: DART is funded by the UK Medical Research Council, the UK Department for International Development (DFID), and the Rockefeller Foundation. GlaxoSmithKline, Gilead and Boehringer-Ingelheim donated first-line drugs for DART, and Abbott provided Kaletra/Aluvia as part of the second-line regimen.